TG Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

TG Therapeutics

28/02/2023 14:08

* TG Therapeutics Inc  TGTX.OQ  reported a quarterly
adjusted loss
of 39 cents​​ per share for the quarter ended in December. The
mean expectation of eight analysts for the quarter was for a
loss of 26 cents per share.
    * Revenue fell 96.6% to $80.00 thousand from a year ago;
analysts
expected $1.83 million. 
    * TG Therapeutics Inc's reported EPS for the quarter was a
loss
of 39 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * TG Therapeutics Inc shares had risen by 34.7% this
quarter.
    * The company reported a quarterly loss of $52.99 million.
    * Wall Street's median 12-month price target for TG
Therapeutics
Inc is $24.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 02:08 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.26          -0.39          Missed
 Sep. 30 2022      -0.34          -0.26          Beat
 Jun. 30 2022      -0.51          -0.30          Beat
 Mar. 31 2022      -0.59          -0.51          Beat